Drug firm Lupin today said it has received approval from the US health regulator to market Fluocinonide Topical ointment, an anti-inflammatory drug, in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) to market generic version of County Line Pharmaceuticals' Lidex ointment, Lupin Ltd said in a statement.
The company said its product is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
As per IMS MAT sales data, Lidex had sales of USD 40.3 million in the US market till March this year.
Lupin shares today ended 1.36 per cent down at Rs 1,018 apiece on BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)